Schlafen, a new family of growth regulatory genes that affect thymocyte development, Immunity, vol.9, pp.657-668, 1998. ,
Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence, Gene, vol.447, pp.1-11, 2009. ,
Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses, J. Biol. Chem, vol.284, pp.25051-25064, 2009. ,
Genetic variation in schlafen genes in a patient with a recapitulation of the murine Elektra phenotype, J. Allergy Clin. Immunol, vol.133, pp.1462-1467, 2014. ,
Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif, International Immunology, vol.16, pp.1535-1548, 2004. ,
Schlafen 3, a novel gene, regulates colonic mucosal growth during aging, Am. J. Physiol. Gastrointest. Liver Physiol, vol.296, pp.955-62, 2009. ,
The Schlafen Family of Proteins and Their Regulation by Interferons, Journal of Interferon & Cytokine Research, vol.33, pp.206-210, 2013. ,
Subcellular localization of the Schlafen protein family, Biochemical and Biophysical Research Communications, vol.370, pp.62-66, 2008. ,
The Schlafen family: complex roles in different cell types and virus replication, Cell Biol Int, vol.10, pp.106-113, 2017. ,
Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells, Results Immunol, vol.5, pp.23-32, 2015. ,
Role of Interferon ? (IFN?)-inducible Schlafen-5 in Regulation of Anchorageindependent Growth and Invasion of Malignant Melanoma Cells, J. Biol. Chem, vol.285, pp.40333-40341, 2010. ,
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11, Nature, vol.491, pp.125-128, 2012. ,
Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation, Molecular Immunology, vol.44, pp.3273-3282, 2007. ,
Schlafen 12 expression modulates prostate cancer cell differentiation, Journal of Surgical Research, vol.190, pp.177-184, 2014. ,
Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1, J. Biol. Chem, vol.280, pp.30723-30734, 2005. ,
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, pp.603-607, 2012. ,
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents, Proc. Natl. Acad. Sci. U.S.A, vol.109, pp.15030-15035, 2012. ,
Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity, DNA Repair, vol.28, pp.107-115, 2015. ,
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs, Oncotarget, vol.7, pp.3084-3097, 2016. ,
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition, pp.1-17, 2016. ,
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer, Clinical Cancer Research, vol.23, pp.523-535, 2017. ,
Schlafen, a new family of growth regulatory genes that affect thymocyte development, Immunity, vol.9, pp.657-68, 1998. ,
The Schlafen family: complex roles in different cell types and virus replication, Cell Biol Int, 2017. ,
Putative DNA/RNA helicase Schlafen 11 (SLFN11) sensitizes cancer cells to DNA damaging agents, Proc Natl Acad Sci, vol.109, pp.15030-15035, 2012. ,
The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, pp.603-610, 2012. ,
Codon usage based inhibition of HIV protein synthesis by human schlafen 11, Nature, vol.491, pp.125-133, 2012. ,
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs, Oncotarget, vol.7, pp.3084-97, 2016. ,
The intra S phase checkpoint affects both DNA replication initiation and elongation: single cell and DNA fiber analyses, Mol Cell Biol, vol.27, pp.5806-5824, 2007. ,
Chk1 and Chk2 kinases in checkpoint control and can cer, Cancer Cell, vol.3, pp.421-430, 2003. ,
The DNA damage response: making it safe to play with knives, Mol Cell, vol.40, pp.179-204, 2010. ,
Trapping of PARP1 and PARP2 by clinical PARP inhibitors, Cancer Res, vol.72, pp.5588-99, 2012. ,
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib, Mol Cancer Ther, vol.13, pp.433-476, 2014. ,
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition, Oncotarget, vol.7, pp.76534-50, 2016. ,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, pp.359-86, 2015. ,
Critical evaluation of secondary cytoreduc tion in recurrent ovarian cancer, Gynecol Oncol, vol.95, pp.273-80, 2004. ,
, Ovarian cancer (including fallopian tube cancer and primary peritoneal cancer
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clini cal Oncology Clinical Practice Guideline, Gynecol Oncol, vol.143, pp.3-15, 2016. ,
Cytoreductive surgery for recurrent ovarian cancer: a meta analysis, Gynecol Oncol, vol.112, pp.265-74, 2009. ,
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review, BMC Cancer, vol.15, p.117, 2015. ,
CA125 in ovarian cancer: European Group on tumor markers guidelines for clinical use, Int J Gynecol Cancer, vol.15, pp.679-91, 2005. ,
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies, PLoS Med, vol.5, p.232, 2008. ,
Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme, Mol Cell, vol.27, pp.262-74, 2007. ,
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome scale analysis, Oncoimmunology, vol.6, p.1253654, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01788951
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, vol.486, pp.346-52, 2012. ,
Clinico pathological and transcriptomic determinants of SLFN11 expres sion in invasive breast carcinoma, J Immunother Cancer, vol.3, p.3, 2015. ,
Genefu: an R/Bioconductor package for computation of gene expression based signatures in breast cancer, Bioinformatics, vol.32, pp.1097-1106, 2016. ,
Multiple correspondence analysis, Encyclopedia of measurement and statistics, pp.651-658, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-01126419
Regularization paths for generalized linear models via coordinate descent, J Stat Softw, vol.33, issue.1, pp.1-22, 2010. ,
,
, A stroma related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer, Nat Med, vol.15, issue.1, pp.68-74, 2009.
Stromal gene expression predicts clinical outcome in breast cancer, Nat Med, vol.14, issue.5, pp.518-545, 2008. ,
Randomized phase III trial comparing biweekly infusional fluoroura cil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC 3, J Clin Oncol, vol.27, pp.3117-3142, 2009. ,
Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial, Clin Cancer Res, vol.15, pp.5528-5561, 2009. ,
Inte grated analysis of molecular and clinical prognostic factors in stage II/III colon cancer, J Natl Cancer Inst, vol.104, pp.1635-1681, 2012. ,
, Cancer genome landscapes. Science, vol.339, pp.1546-58, 2013.
High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin based treatment, BMC Cancer, vol.15, p.833, 2015. ,
Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features, Modern Pathol, vol.26, pp.825-859, 2013. ,
, Article type: Research Article References
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, issue.5, pp.359-86, 2015. ,
K: Recent progress in the diagnosis and treatment of ovarian cancer, CA Cancer J Clin, vol.61, issue.3, pp.183-203, 2011. ,
The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded, Am. J. Pathol, vol.186, issue.4, pp.733-747, 2016. ,
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, Am. J. Surg. Pathol, vol.34, issue.3, pp.433-443, 2010. ,
Ovarian cancer pathogenesis: a model in evolution, J Oncol, vol.2010, p.932371, 2010. ,
New insights into the pathogenesis of serous ovarian cancer and its clinical impact, J. Clin. Oncol, vol.26, issue.32, pp.5284-5293, 2008. ,
,
,
, Nat. Rev. Cancer, vol.15, issue.11, pp.668-679, 2015.
, Ovarian cancer. Lancet, vol.374, issue.9698, pp.1371-1382, 2009.
Adherence to treatment guidelines for ovarian cancer as a measure of quality care, Obstet Gynecol, vol.121, issue.6, pp.1226-1234, 2013. ,
Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo, Oncol. Rep, vol.29, issue.1, pp.58-66, 2013. ,
Relapsed ovarian cancer: challenges and management strategies for a chronic disease, Oncologist, vol.7, pp.20-28, 2002. ,
A: Cancer cell adaptation to chemotherapy, BMC Cancer, vol.5, issue.1, p.78, 2005. ,
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents, Proc Natl Acad Sci, vol.109, issue.37, pp.15030-15035, 2012. ,
C: Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses, J. Biol. Chem, 2009. ,
Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif, Int Immunology, vol.16, issue.10, pp.1535-1548, 2004. ,
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11, Nature, vol.491, issue.7422, pp.125-128, 2012. ,
,
SLFN11 Blocks Stressed Replication Forks Independently of ATR, Mol. Cell, vol.69, issue.3, pp.371-384, 2018. ,
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma, Clinical Cancer Research, vol.21, issue.18, pp.4184-4193, 2015. ,
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan, Anti-Cancer Drugs, vol.25, issue.10, pp.1175-1181, 2014. ,
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs, Oncotarget, vol.7, issue.3, pp.3084-3097, 2016. ,
, Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11
, Expression. Clinical Cancer Research, vol.21, issue.5, pp.1139-1150, 2015.
SLFN11 inhibits checkpoint maintenance and homologous recombination repair, EMBO reports, vol.17, issue.1, pp.94-109, 2016. ,
The Schlafen Family of Proteins and Their Regulation by Interferons, Journal of Interferon & Cytokine Research, vol.33, issue.4, pp.206-210, 2013. ,
Cell blocks in cytopathology: a review of preparative methods, utility in diagnosis and role in ancillary studies, Cytopathology, vol.25, issue.6, pp.356-371, 2014. ,
, Dynamic variations in epithelial-to
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, issue.5, pp.359-86, 2015. ,
Molecular portraits of human breast tumours. Nature, vol.406, pp.747-52, 2000. ,
Gene-expression signatures in breast cancer, N Engl J Med, vol.360, issue.8, pp.790-800, 2009. ,
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes, Breast, vol.24, issue.2, pp.136-178, 2015. ,
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, issue.7391, pp.603-610, 2012. ,
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents ,
, Proc Natl Acad Sci USA. National Academy of Sciences, vol.109, issue.37, pp.15030-15035, 2012.
Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses, J Biol Chem, vol.284, issue.37, pp.25051-64, 2009. ,
Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif, International Immunology, vol.16, issue.10, pp.1535-1583, 2004. ,
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11, Nature ,
The Schlafen Family of Proteins and Their Regulation by Interferons, Journal of Interferon & Cytokine Research, vol.33, issue.4, pp.206-216, 2013. ,
Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence, Gene, vol.447, issue.1, pp.1-11, 2009. ,
Schlafen, a new family of growth regulatory genes that affect thymocyte development, Immunity, vol.9, issue.5, pp.657-68, 1998. ,
Subcellular localization of the Schlafen protein family. Biochemical and Biophysical Research Communications, vol.370, pp.62-68, 2008. ,
SLFN11 Blocks Stressed Replication Forks Independently of ATR, Mol Cell, vol.69, issue.3, pp.371-377, 2018. ,
SLFN11 inhibits checkpoint maintenance and homologous recombination repair, EMBO reports, vol.17, issue.1, pp.94-109, 2016. ,
Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 ,
, SLFN11)expression with class I histone deacetylase inhibitors, Clinical Cancer Research, 2017.
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma, Clinical Cancer Research, vol.21, issue.18, pp.4184-93, 2015. ,
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents, pp.1-6, 2017. ,
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan. Anti-Cancer Drugs, vol.25, pp.1175-81, 2014. ,
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs, Oncotarget, vol.7, issue.3, pp.3084-97, 2016. ,
Methylation of SLFN11is a marker of poor prognosis and cisplatin resistance in colorectal cancer, Epigenomics, 2017. ,
Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer, J Clin Oncol. American Society of Clinical Oncology, p.2018777672, 2018. ,
A threegene model to robustly identify breast cancer molecular subtypes, J Natl Cancer Inst, 2012. ,
, Feb, vol.22, issue.4, pp.311-336
, Comprehensive molecular portraits of human breast tumours. Nature, vol.490, pp.61-70, 2012.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, vol.486, pp.346-52, 2012. ,
DNA methylation profiling reveals a predominant immune component in breast cancers ,
, EMBO Mol Med. EMBO Press, vol.3, issue.12, pp.726-767, 2011.
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis, OncoImmunology, vol.6, issue.2, p.1253654, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01788951
Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer, Bioinformatics, vol.32, issue.7, pp.1097-1106, 2016. ,
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat Protoc, vol.4, issue.1, pp.44-57, 2009. ,
Deconstructing the molecular portraits of breast cancer, Molecular Oncology, vol.5, issue.1, pp.5-23, 2010. ,
Genomic Characterization of Primary Invasive Lobular Breast Cancer, J Clin Oncol, vol.34, issue.16, pp.1872-81, 2016. ,
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis, J Clin Oncol, vol.30, issue.16, pp.1996-2004, 2012. ,
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes, Clinical Cancer Research, vol.14, issue.16, pp.5158-65, 2008. ,
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer, 2017. ,
Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells, Results Immunol, vol.5, pp.23-32, 2015. ,
Prognostic and predictive immune gene signatures in breast cancer, Current Opinion in Oncology, vol.27, issue.6, pp.433-477, 2015. ,
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers, Journal of Clinical Oncology, vol.33, issue.9, pp.983-91, 2015. ,
CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now? Clinical Cancer Research, vol.21, pp.4743-4749, 2015. ,
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis, Breast Cancer Res. BioMed Central, vol.8, issue.3, p.32, 2006. ,
Prognostic stromal gene signatures in breast cancer, Breast Cancer Res. BioMed Central, vol.17, issue.1, p.747, 2015. ,
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer, Nat Med, vol.15, issue.1, pp.68-74, 2009. ,
Stromal gene expression predicts clinical outcome in breast cancer, Nat Med, vol.14, issue.5, pp.518-545, 2008. ,
, CD4+ follicular helper T cell infiltration predicts breast cancer survival, J Clin Invest, vol.123, issue.7, pp.2873-92, 2013.
The good and the bad faces of STAT1 in solid tumours, Cytokine, vol.89, pp.12-20, 2017. ,
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease, vol.13, pp.674-90, 2016. ,
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX, J Clin Oncol, vol.31, issue.25, pp.3083-90, 2013. ,
,
, Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer, vol.116, pp.1431-1440, 2010.
A review of the importance of immune responses in luminal B breast cancer, OncoImmunology, vol.6, issue.3, p.1282590, 2017. ,
Biological subtypes of breast cancer: Prognostic and therapeutic implications, World J Clin Oncol, vol.5, issue.3, pp.412-436, 2014. ,
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness, Cancer Immunol Res, vol.4, issue.7, pp.600-610, 2016. ,
Omics Profiling in Precision Oncology, Molecular & Cellular Proteomics, vol.15, pp.2525-2536, 2016. ,
, Schlafen, a new family of growth regulatory genes that affect thymocyte development, vol.9, pp.657-668, 1998.
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents, Proc Natl Acad Sci, vol.109, pp.15030-15035, 2012. ,
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, pp.603-607, 2012. ,
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer, J Clin Oncol JCO2018777672, 2018. ,
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs, Oncotarget, vol.7, pp.3084-3097, 2016. ,
Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma, Journal for ImmunoTherapy of Cancer, vol.3, pp.3-5, 2015. ,
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11, Nature, vol.491, pp.125-128, 2012. ,
, Schlafen 11 Restricts Flavivirus Replication, 2018.
Schlafen 11 naturally blocks HIV, Nature Reviews Urology, vol.9, pp.605-605, 2012. ,
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma, Clinical Cancer Research, vol.21, pp.4184-4193, 2015. ,
Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression, Clinical Cancer Research, vol.21, pp.1139-1150, 2015. ,
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan, Anti-Cancer Drugs, vol.25, pp.1175-1181, 2014. ,
Methylation of SLFN11is a marker of poor prognosis and cisplatin resistance in colorectal cancer, Epigenomics, vol.9, pp.849-862, 2017. ,
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung, pp.1-13, 2017. ,
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer, Clinical Cancer Research, vol.23, pp.523-535, 2017. ,
SLFN11 Blocks Stressed Replication Forks Independently of ATR, Mol Cell, vol.69, pp.371-384, 2018. ,
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis, Cancer Cell, vol.31, pp.286-299, 2017. ,
Ki67 in breast cancer: prognostic and predictive potential, Lancet Oncology, vol.11, pp.174-183, 2010. ,
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial, Ann Oncol, vol.24, pp.2786-2793, 2013. ,
Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients, Breast Cancer Research and Treatment, vol.153, pp.477-491, 2015. ,
St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods, Breast Cancer Research and Treatment, vol.159, pp.257-263, 2016. ,
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group, J Natl Cancer Inst, vol.103, pp.1656-1664, 2011. ,
Assessment of Ki-67 as a potential biomarker in patients with breast cancer, Journal of Genetic Engineering and Biotechnology, vol.16, pp.479-484, 2018. ,
Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers, Molecular Oncology, vol.8, pp.783-798, 2014. ,
Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers, Clinical Chemistry, vol.61, pp.809-820, 2015. ,